The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Outlook 2024
Synopsis
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market was valued at US$ 1254.6 million in 2020 and is expected to reach US$ 2554.5 million by the end of 2027, growing at a CAGR of 10.7% during 2021-2027.
This report focuses on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
XIFAXAN
Viberzi
Lotronex
Other
Segment by Sales Channel
Hospitals Pharmacy
Retail Pharmacy
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Bausch Health
Allergan
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal Pharms
Pharscin Pharma
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market was valued at US$ 1254.6 million in 2020 and is expected to reach US$ 2554.5 million by the end of 2027, growing at a CAGR of 10.7% during 2021-2027.
This report focuses on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
XIFAXAN
Viberzi
Lotronex
Other
Segment by Sales Channel
Hospitals Pharmacy
Retail Pharmacy
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Bausch Health
Allergan
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal Pharms
Pharscin Pharma
Index1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Overview
1.1 Product Overview and Scope of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 XIFAXAN
1.2.3 Viberzi
1.2.4 Lotronex
1.2.5 Other
1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Sales Channel
1.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Comparison by Sales Channel: (2021-2027)
1.3.2 Hospitals Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Estimates and Forecasts
1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2016-2027
1.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2016-2027
1.4.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region: 2016 Versus 2021 Versus 2027
2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competition by Manufacturers
2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Sites, Area Served, Product Type
2.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Competitive Situation and Trends
2.5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players Market Share by Revenue
2.5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario by Region
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.4.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.4.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
3.5.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.6.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.6.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
3.7.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Analysis by Type
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2021)
4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2016-2021)
4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2016-2021)
5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Analysis by Sales Channel
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2016-2021)
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2016-2021)
5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2016-2021)
6 Key Companies Profiled
6.1 Bausch Health
6.1.1 Bausch Health Corporation Information
6.1.2 Bausch Health Description and Business Overview
6.1.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.1.5 Bausch Health Recent Developments/Updates
6.2 Allergan
6.2.1 Allergan Corporation Information
6.2.2 Allergan Description and Business Overview
6.2.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.2.5 Allergan Recent Developments/Updates
6.3 Sebela Pharmaceuticals
6.3.1 Sebela Pharmaceuticals Corporation Information
6.3.2 Sebela Pharmaceuticals Description and Business Overview
6.3.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.3.5 Sebela Pharmaceuticals Recent Developments/Updates
6.4 Astellas Pharmaceuticals
6.4.1 Astellas Pharmaceuticals Corporation Information
6.4.2 Astellas Pharmaceuticals Description and Business Overview
6.4.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.4.5 Astellas Pharmaceuticals Recent Developments/Updates
6.5 Amneal Pharms
6.5.1 Amneal Pharms Corporation Information
6.5.2 Amneal Pharms Description and Business Overview
6.5.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.5.5 Amneal Pharms Recent Developments/Updates
6.6 Pharscin Pharma
6.6.1 Pharscin Pharma Corporation Information
6.6.2 Pharscin Pharma Description and Business Overview
6.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
6.6.5 Pharscin Pharma Recent Developments/Updates
7 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Cost Analysis
7.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
7.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
8.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
9 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Dynamics
9.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
9.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Growth Drivers
9.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges
9.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
10 Global Market Forecast
10.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2022-2027)
10.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Sales Channel
10.2.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel (2022-2027)
10.2.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel (2022-2027)
10.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) Comparison by Sales Channel (2021-2027)
Table 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Covered in This Study
Table 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2016-2021) & (K Units)
Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2016-2021)
Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021) & (K Units)
Table 19. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2016-2021)
Table 20. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2016-2021)
Table 22. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021) & (K Units)
Table 23. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2016-2021)
Table 24. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2016-2021)
Table 30. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2016-2021)
Table 32. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2016-2021)
Table 38. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) by Type (2016-2021)
Table 39. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2021)
Table 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) by Type (2016-2021)
Table 41. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2016-2021)
Table 42. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Type (2016-2021)
Table 43. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) by Sales Channel (2016-2021)
Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2016-2021)
Table 45. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Million US$) by Sales Channel (2016-2021)
Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Sales Channel (2016-2021)
Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Sales Channel (2016-2021)
Table 48. Bausch Health Corporation Information
Table 49. Bausch Health Description and Business Overview
Table 50. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
Table 52. Bausch Health Recent Developments/Updates
Table 53. Allergan Corporation Information
Table 54. Allergan Description and Business Overview
Table 55. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
Table 57. Allergan Recent Developments/Updates
Table 58. Sebela Pharmaceuticals Corporation Information
Table 59. Sebela Pharmaceuticals Description and Business Overview
Table 60. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
Table 62. Sebela Pharmaceuticals Recent Developments/Updates
Table 63. Astellas Pharmaceuticals Corporation Information
Table 64. Astellas Pharmaceuticals Description and Business Overview
Table 65. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
Table 67. Astellas Pharmaceuticals Recent Developments/Updates
Table 68. Amneal Pharms Corporation Information
Table 69. Amneal Pharms Description and Business Overview
Table 70. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
Table 72. Amneal Pharms Recent Developments/Updates
Table 73. Pharscin Pharma Corporation Information
Table 74. Pharscin Pharma Description and Business Overview
Table 75. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
Table 77. Pharscin Pharma Recent Developments/Updates
Table 78. Production Base and Market Concentration Rate of Raw Material
Table 79. Key Suppliers of Raw Materials
Table 80. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
Table 81. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List
Table 82. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Trends
Table 83. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Growth Drivers
Table 84. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges
Table 85. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
Table 86. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2022-2027) & (K Units)
Table 87. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Type (2022-2027)
Table 88. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 89. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 90. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Sales Channel (2022-2027) & (K Units)
Table 91. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Sales Channel (2022-2027)
Table 92. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Sales Channel (2022-2027) & (US$ Million)
Table 93. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Sales Channel (2022-2027)
Table 94. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Region (2022-2027) & (K Units)
Table 95. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Region (2022-2027)
Table 96. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 97. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Type in 2020 & 2027
Figure 3. XIFAXAN Product Picture
Figure 4. Viberzi Product Picture
Figure 5. Lotronex Product Picture
Figure 6. Other Product Picture
Figure 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Sales Channel in 2020 & 2027
Figure 8. Hospitals Pharmacy
Figure 9. Retail Pharmacy
Figure 10. Other
Figure 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size 2016-2027 (US$ Million)
Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2016-2027 (K Units)
Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 15. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers in 2020
Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers in 2020
Figure 17. The Global 5 and 10 Largest Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players: Market Share by Revenue in 2020
Figure 18. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2016-2021)
Figure 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region in 2020
Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2016-2021)
Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region in 2020
Figure 23. U.S. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type (2016-2021)
Figure 46. Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel (2016-2021)
Figure 47. Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel in 2020
Figure 48. Revenue Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel (2016-2021)
Figure 49. Revenue Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel in 2020
Figure 50. Manufacturing Cost Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 51. Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 52. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
